IFO50312 SNG-II
Cell information
Cell type：general cells (View Pricing Information)
| JCRB No. | IFO50312 | Cell Name | SNG-II |
|---|---|---|---|
| Profile | endometrial adenocarcinoma | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | F | Age | 43 |
| Identity | available | Tissue for Primary Cancer | uterus |
| Case history | endometrial adenocarcinoma | Metastasis | |
| Tissue Metastasized | Genetics | ||
| Life Span | infinite | Crisis PDL | |
| Morphology | Character | endometrial adenocarcinoma | |
| Classify | tumor | Established by | Nozawa, S. |
| Registered by | Nozawa,S. | Regulation for Distribution | |
| Comment | This cell line does not contain a DNA sequence for E6 oncogene of HPV type 16, 18 and 33. (Tested at IFO (PCR)). | Year | 1991 |
| Medium | Ham's F12 medium with 10% fetal bovine serum | Methods for Passages | trypsin-EDTA |
| Cell Number on Passage | Race | ||
| CO2 Conc. | 5 % | Tissue Sampling | uterine endometrium |
| Tissue Type |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | |||||||||
| Reference | |
|---|---|
| Pubmed id:3295079 | [Production of monoclonal antibody against a newly established human endometrial cancer cell line SNG-II]. Nozawa S,Sakayori M,Takayama Y,Tsukazaki K,Aoki D,Iizuka R,Mukai M,Inaba N Nihon Sanka Fujinka Gakkai Zasshi. 1987 Apr;39(4):559-66 |
| Images |
|---|
   |
| Movies |
|---|
|
LOT Information
| Cell No. | IFO50312 | Cell Name | SNG-II |
|---|---|---|---|
| LOT No. | 1117 | Lot Specification | distribution |
| Medium | Ham's F12, 90% ; FBS, 10% | Temperature | 37 C |
| Cell Density at Seeding | Methods for Passages | trypsin-EDTA | |
| Doubling Time | Cell Number in Vial (cells/1ml) | 1 x 10^6 | |
| Viability at cell freezing (%) | 89 | Antibiotics Used | free |
| Passage Number | Unknown (14 at IFO) | PDL | |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NP, G6PD (type B), MD |
| Chromosome Mode | Chromosome Information | ||
| Surface Antigen | DNA Profile (STR) | D5S818:6,12 D13S317:9,12 D7S820:9,13 D16S539:12,13 VWA:15,16,17 TH01:9 AM:X TPOX:11 CSF1PO:11,14 |
|
| Adhesion | Exoteric Gene | ||
| Medium for Freezing | 10% DMSO, 20% serum (final conc.) - culture medium | CO2 Conc. | |
| Viability immediately after thawing (%) | Additional information | Ampule lot# is labeled as R699F1117. |
| Images |
|---|
|
|
| Cell No. | IFO50312 | Cell Name | SNG-II |
|---|---|---|---|
| LOT No. | 09102015 | Lot Specification | distribution |
| Medium | Ham's F12 medium with 10% fetal bovine serum (FBS; GIBCO Cat. # 10091) | Temperature | 37 C |
| Cell Density at Seeding | 3.5 - 4.0 x 10^4 cells/mL | Methods for Passages | Cells were harvested after treatment with 0.25% trypsin and 0.02% EDTA. |
| Doubling Time | 30 - 41 hrs. | Cell Number in Vial (cells/1ml) | 8.3 x 10^5 |
| Viability at cell freezing (%) | 64.6 | Antibiotics Used | free |
| Passage Number | Unknown (14 at bank) | PDL | |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | |
| Chromosome Mode | Chromosome Information | ||
| Surface Antigen | DNA Profile (STR) | ||
| Adhesion | Yes | Exoteric Gene | |
| Medium for Freezing | 10% DMSO, 20% FBS - F12 | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | 64.6 | Additional information |